Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 480

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial

Open access
Sprigg, Nikola, Flaherty, Katie, Appleton, Jason P, Salman, Rustam Al-Shahi, Bereczki, Daniel, Beridze, Maia, Christensen, Hanne, Ciccone, Alfonso, Collins, Ronan, Czlonkowska, Anna, Dineen, Robert A, Duley, Lelia, Egea-Guerrero, Juan Jose, England, Timothy J, Krishnan, Kailash, Laska, Ann Charlotte, Law, Zhe Kang, Ozturk, Serefnur, Pocock, Stuart J, Roberts, Ian, Robinson, Thompson G, Roffe, Christine, Seiffge, David, Scutt, Polly, Thanabalan, Jegan, Werring, David, Whynes, David, Bath, Philip M·2018·The Lancet

Abstract

BACKGROUND: Tranexamic acid can prevent death due to bleeding after trauma and post-partum haemorrhage. We aimed to assess whether tranexamic acid reduces haematoma expansion and improves outcome in adults with stroke due to intracerebral haemorrhage. METHODS: We did an international, randomised placebo-controlled trial in adults with intracerebral haemorrhage from acute stroke units at 124 hospital sites in 12 countries. Participants were randomly assigned (1:1) to receive 1 g intravenous tranexamic acid bolus followed by an 8 h infusion of 1 g tranexamic acid or a matching placebo, within 8 h of symptom onset. Randomisation was done centrally in real time via a secure website, with stratification by country and minimisation on key prognostic factors. Treatment allocation was concealed from patients, outcome assessors, and all other health-care workers involved in the trial. The primary outcome was functional status at day 90, measured by shift in the modified Rankin Scale, using ordinal logistic regression with adjustment for stratification and minimisation criteria. All analyses were done on an intention-to-treat basis. This trial is registered with the ISRCTN registry, number ISRCTN93732214. FINDINGS: We recruited 2325 participants between March 1, 2013, and Sept 30, 2017. 1161 patients received tranexamic acid and 1164 received placebo; the treatment groups were well balanced at baseline. The primary outcome was assessed for 2307 (99%) participants. The primary outcome, functional status at day 90, did not differ significantly between the groups (adjusted odds ratio [aOR] 0·88, 95% CI 0·76-1·03, p=0·11). Although there were fewer deaths by day 7 in the tranexamic acid group (101 [9%] deaths in the tranexamic acid group vs 123 [11%] deaths in the placebo group; aOR 0·73, 0·53-0·99, p=0·0406), there was no difference in case fatality at 90 days (250 [22%] vs 249 [21%]; adjusted hazard ratio 0·92, 95% CI 0·77-1·10, p=0·37). Fewer patients had serious adverse events after tranexamic acid than after placebo by days 2 (379 [33%] patients vs 417 [36%] patients), 7 (456 [39%] vs 497 [43%]), and 90 (521 [45%] vs 556 [48%]). INTERPRETATION: Functional status 90 days after intracerebral haemorrhage did not differ significantly between patients who received tranexamic acid and those who received placebo, despite a reduction in early deaths and serious adverse events. Larger randomised trials are needed to confirm or refute a clinically significant treatment effect. FUNDING: National Institute of Health Research Health Technology Assessment Programme and Swiss Heart Foundation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(18)31033-x

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 480

Metadata

Authors
Sprigg, N., Flaherty, K., Appleton, J. P., Salman, R. A.-S., Bereczki, D., Beridze, M., Christensen, H., Ciccone, A., Collins, R., Czlonkowska, A., Dineen, R. A., Duley, L., Egea-Guerrero, J. J., England, T. J., Krishnan, K., Laska, A. C., Law, Z. K., Ozturk, S., Pocock, S. J., Roberts, I., Robinson, T. G., Roffe, C., Seiffge, D., Scutt, P., Thanabalan, J., Werring, D., Whynes, D., & Bath, P. M.
Venue
The Lancet
Publisher
Elsevier BV
Published
2018-05
Volume
391
Issue
10135
Pages
2107-2115
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2804714053
Cited by
480
References
28
FWCI
30.53
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial. https://app.cochat.ai/papers/10.1016/s0140-6736(18)31033-x
The paper
Sprigg, N., Flaherty, K., Appleton, J. P., Salman, R. A.-S., Bereczki, D., Beridze, M., Christensen, H., Ciccone, A., Collins, R., Czlonkowska, A., Dineen, R. A., Duley, L., Egea-Guerrero, J. J., England, T. J., Krishnan, K., Laska, A. C., Law, Z. K., Ozturk, S., Pocock, S. J., . . . Bath, P. M. (2018). Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial. The Lancet. https://doi.org/10.1016/s0140-6736(18)31033-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.